Holkova, B., Zingone, A., Kmieciak, M., Bose, P., Badros, A. Z., Voorhees, P. M., . . . Grant, S. (2015). A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res.
Citação norma ChicagoHolkova, Beata, et al. "A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma." Clin Cancer Res 2015.
Citação norma MLAHolkova, Beata, et al. "A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma." Clin Cancer Res 2015.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.